Lung Cancer Screening (LCS)
Lack of diagnostic accuracy is a major hurdle for screening program implementation and adherence
Lung cancer prognosis is the poorest of all common cancers, largely due to a high proportion of cases being detected at an advanced stage
A stage shift in lung cancer diagnosis would have a dramatic impact on lowering overall mortality
Median’s iBiopsy® LCS
Unrivalled AI/ML Software as Medical Device (SaMD) enabling early lung cancer diagnosis with unprecedented performance
End-to-end AI/ML tech-based CADe CADx for early diagnosis in lung cancer screening programs
Indicated for the detection, localization, and characterization of pulmonary nodules into suspicious/malignant
Unprecedented sensitivity and specificity versus standard of care
A radiological CADe device is “intended to identify, mark, highlight or otherwise direct attention to portions of an image that may reveal abnormalities during interpretation of images by the clinician”. A CADx device is “intended to provide information beyond identifying abnormalities, such as an assessment of disease”. Source: FDA
Additional indications
Liver cancer
Very early hepatocellular carcinoma (HCC)
Liver fibrosis
Liver fibrosis in non-alcoholic steatohepatitis (NASH)
Latest news
PRESS RELEASE
Median Technologies to participate in the 2022 European Congress of Radiology (ECR), July 13 – 17, 2022, Vienna, Austria, with two presentations on iBiopsy®
PRESS RELEASE
Median Technologies is moving forward with the FDA interactions for its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device
PRESS RELEASE
Median Technologies announces design completion of its iBiopsy® Lung Cancer Screening end-to-end CADe/CADx Software as Medical Device (SaMD) with outstanding sensitivity & specificity performance
